Pentobarbital veterinary grade API is supplied as a white or almost white crystalline powder for formulation into tablets, injections, capsules, powders, granules, premixes, and solutions. The free acid, C₁₁H₁₈N₂O₃, has a relative molecular mass of 226.27 and CAS RN 76-74-4; the sodium salt, C₁₁H₁₇N₂NaO₃, has a relative molecular mass of 248.25 and CAS RN 57-33-0. The product is released under the code PENT-V-API-NA for the parenteral and solution grade and PENT-V-API-FA for the solid oral grade. The active substance is a short-acting oxybarbiturate used in licensed veterinary formulations for anesthetic induction, sedation, and, where legally authorized, humane euthanasia. The physical form is selected according to the dosage form: the sodium salt is freely soluble in water and is used in injectable solutions and aqueous granulation, while the free acid is used in non-aqueous granulation, capsule filling, and premix powders to reduce hygroscopicity.

A single API grade is not suitable for all dosage forms because particle size, salt form, moisture content, and surface area affect dissolution, content uniformity, and chemical stability differently. The release specification therefore includes form-specific particle size distribution: the sodium salt for parenteral use is milled to a D50 of 25–75 µm, whereas the free acid for capsule and premix applications is controlled to a D90 of ≤150 µm with a target span of 1.8–2.4 to minimize segregation. The material is packaged in double low-density polyethylene bags inside an aluminum-laminated foil pouch with desiccant; headspace oxygen is limited to ≤0.5% v/v for the sodium salt because surface oxidative discoloration occurs at elevated humidity.

Pharmacopoeial Alignment and Release Specification

Release is performed against the battery of methods listed in Table 1. The acceptance limits are representative of current veterinary API certificates and are aligned with the relevant monographs for pentobarbital sodium and pentobarbital free acid where pharmacopoeial texts exist. Values outside the stated ranges are not released without a documented risk assessment.

The HPLC method for related substances uses a C18 column with 150 mm × 4.6 mm internal diameter, 5 µm particle size, and a mobile phase of acetonitrile and pH 7.0 phosphate buffer at a flow rate of 1.0 mL/min with UV detection at 210 nm. System suitability requires resolution between pentobarbital and the nearest specified process impurity of not less than 2.0, tailing factor not more than 2.0, and relative standard deviation of six replicate injections not more than 2.0%. The method is validated for specificity, linearity from 0.1% to 150% of the nominal concentration, and accuracy between 98.0% and 102.0% at three levels.

Direct compression of the free acid for tablets at strengths between 25 mg and 100 mg is generally limited to formulations with a drug load above 5% w/w, since lower loadings increase the risk of content uniformity failure. The milled free acid is pre-blended with microcrystalline cellulose and crospovidone in a high-shear mixer at 150 rpm for 3 min; a geometric dilution sequence with 0.5% w/w colloidal silicon dioxide is used when the final blend assay is below 10% w/w. The blend is lubricated with magnesium stearate at 0.25–0.5% w/w; lubrication above 1.0% w/w creates a hydrophobic film that reduces tablet tensile strength and increases disintegration time beyond 15 min in USP <701>. The tablet press is operated with a pre-compression force of 5–7 kN and a main compression force of 12–18 kN; higher forces above 20 kN can cause capping because the free acid has low elastic recovery but high brittleness. Ejection force is monitored below 800 N; if ejection force exceeds this threshold, the formulation is adjusted with 0.5% w/w sodium stearyl fumarate or by increasing the granulation moisture to 2.0% w/w.

For capsule filling, the free acid is blended with lactose monohydrate and pregelatinized starch; the target fill weight is 120–180 mg for a 50 mg strength. The powder is filled into hard gelatin capsules using a dosator machine with a pin setting of 3.5–4.0 mm; the fill weight variability is maintained below ±3% to meet USP <905>. Capsules are stored with desiccant because the sodium salt, if used, can crosslink gelatin at capsule shell moisture contents above 18%, leading to brittle caps.

Powder and granule dose forms for oral administration are produced by wet granulation with a hydroalcoholic binder containing ethanol and povidone; the granulation is dried in a fluid bed at inlet air temperature 60 °C to a loss on drying of 1.0–2.0% w/w. The dried granules are screened through 16 mesh and 40 mesh; the fraction between 40 mesh and 80 mesh is retained for filling to reduce dust and improve flow. For oral powders, the sodium salt is mixed with anhydrous dextrose and sodium citrate to a final concentration of 2 mg/g; the powder blend is filled into unit-dose sachets under relative humidity ≤30% to prevent agglomeration. The fill weight is 1.0–2.0 g per sachet; content uniformity tested by USP <905> requires 10 units with an acceptance value of ≤15.0.

Oral solutions prepared from the sodium salt at concentrations of 5–20 mg/mL are buffered to pH 8.5–9.5 and preserved with sodium benzoate at 0.1% w/v or parabens at 0.08–0.15% w/v. These solutions are filled into amber glass bottles because exposure to light above 200 lux accelerates photodegradation; the specification includes a color limit of ≤Y5 in the Gardner scale. Published data for this specific liquid formulation configuration is limited; stability should be confirmed by bracketing studies at 25 °C/60% RH and 40 °C/75% RH for not less than 6 months.

What Limits the Sterility Assurance Level of Pentobarbital Sodium Injection Solutions?

For injectable solutions and aqueous veterinary products, pentobarbital sodium is dissolved in water for injection at concentrations between 50 mg/mL and 200 mg/mL. The solution is buffered to a pH of 9.0–10.5 with sodium hydroxide or glycine buffer to maintain the active substance in the ionized form and to suppress oxidative degradation. Dissolved oxygen is reduced to ≤0.5 ppm by nitrogen sparging before filling; ampoules or vials are blanketed with nitrogen during filling to minimize formation of 5-ethyl-5-(1-methylbutyl)barbituric acid oxidation products. Terminal sterilization is carried out at 121 °C for 15 min using a saturated-steam autoclave cycle validated to a minimum F0 of 15 min. The load is monitored with biological indicators containing Geobacillus stearothermophilus spores at 10⁶ CFU per unit and a D₁₂₁ of 1.5–2.0 min, yielding a predicted sterility assurance level below 10⁻⁶ per USP <71>. Filter integrity testing of the 0.22 µm sterilizing-grade filter is performed before and after filtration; bubble point must exceed 3.2 bar for PVDF membrane filters. Particulate matter is controlled under USP <788> to not more than 6000 particles per container ≥10 µm and 600 particles per container ≥25 µm for small-volume injections. The principal process failure modes are pH drift after filling and residual oxygen in the headspace; both can reduce assay to below 95% during six-month stability storage at 40 °C/75% RH.

Granulation for premix feed applications uses a different API particle size specification. The API is first adsorbed onto calcium carbonate or silicon dioxide at a mass ratio of 1:9 to 1:19 to reduce electrostatic adhesion and improve flow. The blend is then mixed in a ribbon blender at 20 rpm for 10 min; sampling at 10 points is performed after 5 min and 10 min to establish homogeneity. An assay value within ±5% of the theoretical concentration at all sampling points is required before discharge. The final premix is packaged in heat-sealed bags with a moisture-barrier layer; total aerobic microbial count is controlled at ≤10² CFU/g, and combined yeast and mold count at ≤10¹ CFU/g, in line with veterinary feed premix GMP. The main segregation risk is the particle size difference between the milled API and the carrier lactose; if the carrier D50 is 150–200 µm while the API D90 is ≤75 µm, the mixture can segregate during transfer. This is mitigated by matching the API D90 to the carrier D50 and by using 0.5% w/w deagglomerating silica.

When the Free Acid Replaces the Sodium Salt in Solid Dosage Forms

The free acid and sodium salt differ in solubility, hygroscopicity, and compatibility with organic solvents. The free acid is practically insoluble in water but freely soluble in ethanol; the sodium salt is freely soluble in water and very soluble in ethanol. This difference allows anhydrous granulation and capsule filling with the free acid to avoid moisture-induced hydrolysis that can occur when the sodium salt contacts aqueous binder systems. However, the free acid has a slower dissolution rate in gastric and intestinal media; tablet formulations using the free acid therefore require a disintegrant such as crospovidone at 3–5% w/w and a wetting agent such as sodium lauryl sulfate at 0.5–1.0% w/w to achieve USP <711> dissolution of not less than 75% in 45 min in 0.1 M hydrochloric acid. The sodium salt is generally preferred for solutions and injections because it forms a clear aqueous solution without pH adjustment below 9.0; the free acid would require organic co-solvents such as propylene glycol or ethanol above 20% v/v, which may cause injection-site irritation and is unsuitable for intravenous administration.

Differences from phenobarbital and secobarbital APIs are measurable in pKa, lipid solubility, and onset. Pentobarbital has a pKa near 8.0 and is a short-acting oxybarbiturate; phenobarbital has a pKa near 7.4 and is a long-acting barbiturate used in anticonvulsant veterinary therapy. Secobarbital has a pKa near 7.9 and a more rapid onset but shorter duration; its sodium salt is also soluble, but its powder is more hygroscopic. The partitioning of pentobarbital into lipid membranes is lower than that of secobarbital but higher than that of phenobarbital based on octanol-water partition coefficients; published comparative data are limited for the non-ionized species at pH 7.4. These differences affect formulation choices: phenobarbital free acid is frequently used in oral tablets where prolonged absorption is acceptable, whereas pentobarbital sodium is used in injectable solutions where rapid effect is required. For solid feed or premix applications, pentobarbital free acid is selected for its lower hygroscopicity compared with sodium pentobarbital and secobarbital sodium.

Compared with a human-grade API, the veterinary grade releases to a modified endotoxin limit and permits certain residual solvent levels according to veterinary product applications. However, no difference in chromatographic purity is acceptable below 98.0%; the manufacturing line is segregated from beta-lactam and cephalosporin processing to avoid cross-contamination. Cleaning validation uses no observed effect level calculations with a maximum allowable carryover of 1/1000 of the therapeutic dose and 10 ppm limit per 21 CFR 211.67.

Because pentobarbital is subject to controlled-substance regulation in many jurisdictions, the veterinary API is manufactured, stored, and shipped under reconciliation and audit trail records. In the United States, the sodium salt and free acid are controlled under the applicable schedule of the Controlled Substances Act; the exact scheduling may vary by jurisdiction. The API is supplied only to licensed veterinary pharmaceutical manufacturers, compounded products, or registered facilities with DEA- or equivalent national authorization. The certificate of analysis includes an auditable batch record and a tamper-evident seal number; chain-of-custody documentation is retained for the period required by 21 CFR 211.180. No data are generated for human clinical use, and the product is not assigned a human-grade pharmacopoeial monograph unless the same substance is separately manufactured under a human API file.

Compatibility limitations are specific: pentobarbital sodium is incompatible with strongly acidic aqueous solutions below pH 6.0, which protonate the free acid and cause precipitation; it should not be mixed with calcium-containing diluents because calcium salts of barbiturates are poorly soluble. Oxidizing agents such as peroxides and hypochlorites must be excluded from cleaning operations for manufacturing equipment because they degrade the barbiturate ring. The API is stable when stored at 15–25 °C in a desiccated environment; excursions above 30 °C for more than 30 days require re-testing of assay and related substances. The free acid is stable for 36 months in unopened original packaging; the sodium salt is assigned a 24-month retest date when stored at ≤25 °C and ≤30% RH.